C2N Diagnostics has partnered with Mediford Corporation, a subsidiary of PHC Holdings, to enhance access to its clinical research services in Japan.
C2N’s Precivity™ blood tests provide highly accurate identification and quantification of biomarkers related to neurological diseases, including Alzheimer’s disease. The tests aid in diagnosis, prognosis, and treatment monitoring. Notably, C2N’s innovative MTBR-tau biomarker aims to detect neurofibrillary tangles associated with tau protein aggregation in the brain.
This partnership expands C2N’s global footprint and leverages Mediford’s extensive network in the Japanese biopharma industry. Maki Hoshiko, a renowned neuroscientist, has been appointed to lead C2N’s Japan strategy and collaborations.
Japan has a high prevalence of Alzheimer’s disease, with 26% of diagnosed cases globally. The country also has the highest proportion of people with dementia.
C2N’s biomarkers are used in multiple clinical trials, including the Clarity AD trial for lecanemab and the TRAILBLAZER-ALZ 2 trial for donanemab. They help improve clinical trial enrollment efficiency and cost-effectiveness.
C2N’s partnership with Mediford demonstrates its commitment to expanding its reach and providing access to advanced biomarker research services worldwide. The collaboration aims to accelerate the development of treatments and improve patient care for neurological conditions.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
